Outline of therapeutic interventions with muscarinic receptor-mediated transmission
- PMID: 24564657
- DOI: 10.33549/physiolres.932675
Outline of therapeutic interventions with muscarinic receptor-mediated transmission
Abstract
Muscarinc receptor-mediated signaling takes part in many physiological functions ranging from complex higher nervous activity to vegetative responses. Specificity of action of the natural muscarinic agonist acetylcholine is effected by action on five muscarinic receptor subtypes with particular tissue and cellular localization, and coupling preference with different G-proteins and their signaling pathways. In addition to physiological roles it is also implicated in pathologic events like promotion of carcinoma cells growth, early pathogenesis of neurodegenerative diseases in the central nervous system like Alzheimer's disease and Parkinson's disease, schizophrenia, intoxications resulting in drug addiction, or overactive bladder in the periphery. All of these disturbances demonstrate involvement of specific muscarinic receptor subtypes and point to the importance to develop selective pharmacotherapeutic interventions. Because of the high homology of the orthosteric binding site of muscarinic receptor subtypes there is virtually no subtype selective agonist that binds to this site. Activation of specific receptor subtypes may be achieved by developing allosteric modulators of acetylcholine binding, since ectopic binding domains on the receptor are less conserved compared to the orthosteric site. Potentiation of the effects of acetylcholine by allosteric modulators would be beneficial in cases where acetylcholine release is reduced due to pathological conditions. When presynaptic function is severely compromised, the utilization of ectopic agonists can be a thinkable solution.
Similar articles
-
Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.Trends Pharmacol Sci. 2019 Dec;40(12):1006-1020. doi: 10.1016/j.tips.2019.10.007. Epub 2019 Nov 8. Trends Pharmacol Sci. 2019. PMID: 31711626 Free PMC article. Review.
-
The Muscarinic Acetylcholine Receptor M5: Therapeutic Implications and Allosteric Modulation.ACS Chem Neurosci. 2019 Mar 20;10(3):1025-1034. doi: 10.1021/acschemneuro.8b00481. Epub 2018 Oct 17. ACS Chem Neurosci. 2019. PMID: 30280567 Review.
-
Muscarinic acetylcholine receptors as CNS drug targets.Pharmacol Ther. 2008 Feb;117(2):232-43. doi: 10.1016/j.pharmthera.2007.09.009. Epub 2007 Dec 20. Pharmacol Ther. 2008. PMID: 18082893 Review.
-
Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.Auton Autacoid Pharmacol. 2006 Jul;26(3):219-33. doi: 10.1111/j.1474-8673.2006.00368.x. Auton Autacoid Pharmacol. 2006. PMID: 16879488 Review.
-
Overview of muscarinic receptor subtypes.Handb Exp Pharmacol. 2012;(208):3-28. doi: 10.1007/978-3-642-23274-9_1. Handb Exp Pharmacol. 2012. PMID: 22222692 Review.
Cited by
-
Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors.Sci Rep. 2017 Jan 16;7:40381. doi: 10.1038/srep40381. Sci Rep. 2017. PMID: 28091608 Free PMC article.
-
Current approaches for the discovery of drugs that deter substance and drug abuse.Expert Opin Drug Discov. 2014 Nov;9(11):1319-31. doi: 10.1517/17460441.2014.956721. Epub 2014 Sep 24. Expert Opin Drug Discov. 2014. PMID: 25251069 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical